RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) on Friday authorized a new cannabis-based drug. The decision was released in a statement by the agency.
Alafiamed 200 mg/ml Cannabis Sativa Extract is obtained from the plant extract of Cannabis sativa, popularly known as marijuana.
The text says the drug is manufactured in Switzerland and will be imported and distributed in Brazil as a finished product ready for use. According to the agency, the drug will be available as a drop solution, containing cannabidiol (CBD) tetrahydrocannabinol (THC) - substances from the plant.
With this new approval, in all . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here